Cargando…

Impact of investigational microbiota therapeutic RBX2660 on the gut microbiome and resistome revealed by a placebo-controlled clinical trial

BACKGROUND: Intestinal microbiota restoration can be achieved by complementing a subject’s perturbed microbiota with that of a healthy donor. Recurrent Clostridioides difficile infection (rCDI) is one key application of such treatment. Another emerging application of interest is reducing antibiotic-...

Descripción completa

Detalles Bibliográficos
Autores principales:	Kwak, Suryang, Choi, JooHee, Hink, Tiffany, Reske, Kimberly A., Blount, Kenneth, Jones, Courtney, Bost, Margaret H., Sun, Xiaoqing, Burnham, Carey-Ann D., Dubberke, Erik R., Dantas, Gautam
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2020
Materias:	Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7457799/ https://www.ncbi.nlm.nih.gov/pubmed/32862830 http://dx.doi.org/10.1186/s40168-020-00907-9

Ejemplares similares

Microbiome Restoration by RBX2660 Does Not Preclude Recurrence of Multidrug-Resistant Urinary Tract Infection Following Subsequent Antibiotic Exposure: A Case Report
por: Keen, Eric C, et al.
Publicado: (2020)

1773. Impact of Antibiotics Used to Treat Community Acquired Pneumonia on the Gut Microbiome and Resistome in Healthy Volunteers
por: Anthony, Winston, et al.
Publicado: (2018)

669. Twelve-Month Durability of Microbiota-Based Therapy RBX2660 for Prevention of Recurrent Clostridium difficile Infection
por: Jones, Courtney, et al.
Publicado: (2019)

Acute and persistent effects of commonly used antibiotics on the gut microbiome and resistome in healthy adults
por: Anthony, Winston E., et al.
Publicado: (2022)

Restoration of Bacterial Microbiome Composition and Diversity Among Treatment Responders in a Phase 2 Trial of RBX2660: An Investigational Microbiome Restoration Therapeutic
por: Blount, Ken F, et al.
Publicado: (2019)

Successful Response to Microbiota-Based Drug RBX2660 in Patients with Recurrent Clostridium Difficile Infection is Associated with More Pronounced Alterations in Microbiome Profile
por: Khanna, Sahil, et al.
Publicado: (2017)

Microbiota restoration reduces antibiotic-resistant bacteria gut colonization in patients with recurrent Clostridioides difficile infection from the open-label PUNCH CD study
por: Langdon, Amy, et al.
Publicado: (2021)

670. VRE Clearance in Patients with Recurrent Clostridium difficile Infection Following Treatment with Microbiota-Based Drug RBX2660
por: Hau, Heidi, et al.
Publicado: (2019)

Durable reduction of Clostridioides difficile infection recurrence and microbiome restoration after treatment with RBX2660: results from an open-label phase 2 clinical trial
por: Orenstein, Robert, et al.
Publicado: (2022)

1950. Prevention of Recurrent Clostridium difficile at Six Months Following Treatment With Microbiota-Based Therapy RBX2660: Durability Results From a Phase 2 Open-Label Study
por: Mische, Sarah, et al.
Publicado: (2018)

Final Results from a Phase 2b Randomized, Placebo-Controlled Clinical Trial of RBX2660: A Microbiota-Based Drug for the Prevention of Recurrent Clostridioides difficile Infection
por: Dubberke, Erik R., et al.
Publicado: (2022)

Etiology of Infectious Diarrhea in Patients Tested for Clostridium difficile: If It Isn’t Clostridium difficile, What Is It?
por: Kwon, Jennie H, et al.
Publicado: (2017)

2322: The effects of fecal microbiota transplantation on the gut microbiota in subjects with Clostridium difficile infection
por: Elizabeth Langdon, Amy, et al.
Publicado: (2018)

468 RBX2660 (microbiota suspension) for Recurrent C. difficile Infection: 60-Day Interim Analysis of the PUNCH-CD Phase 2 Safety Study
por: Dubberke, Erik, et al.
Publicado: (2014)

The Role of Microbiome-Based Therapeutics in Clostridioides difficile Infection: Durable, Long-Term Results of RBX2660
por: Orenstein, Robert
Publicado: (2022)

Impact of Amoxicillin-Clavulanate followed by Autologous Fecal Microbiota Transplantation on Fecal Microbiome Structure and Metabolic Potential
por: Bulow, Christopher, et al.
Publicado: (2018)

2847. Comparative Genomics and Clonal Tracking of Multi-drug-Resistant Uropathogens Implicates the Fecal Microbiome as a Potential Reservoir for Recurrent Urinary Tract Infections
por: Thanert, Robert, et al.
Publicado: (2019)

29. Rapid Restoration of Bile Acid Compositions After Treatment with Investigational Microbiota-based Therapeutic RBX2660 for Recurrent clostrioides Difficile Infection
por: Ferdyan, Nicky, et al.
Publicado: (2020)

Multi-omics investigation of Clostridioides difficile-colonized patients reveals pathogen and commensal correlates of C. difficile pathogenesis
por: Fishbein, Skye RS, et al.
Publicado: (2022)

129. Antimicrobial Resistance Genes Were Reduced Following Administration of Investigational Microbiota-Based Live Biotherapeutic RBX2660 to Individuals with Recurrent Clostridioides difficile Infection
por: Hau, Heidi, et al.
Publicado: (2021)

522. Significant Improvement in Health-Related Quality of Life (HRQL) with RBX2660: Results from a Phase 3 Randomized, Placebo-Controlled Trial in Recurrent Clostridioides Difficile Infection (PUNCH CD3)
por: Feuerstadt, Paul, et al.
Publicado: (2022)

236. Treatment of Recurrent Clostridioides difficile Infection With RBX2660 in Patients ≥ 65 Years Old With Underlying Comorbidities
por: Tillotson, Glenn S, et al.
Publicado: (2022)

1039. Rapid Restoration of Bile Acid Compositions After Treatment with RBX2660 for Recurrent Clostridioides difficile Infection—Results from the PUNCH CD3 Phase 3 Trial
por: Papazyan, Romeo, et al.
Publicado: (2021)

Randomized Controlled Trial of Oral Vancomycin Treatment in Clostridioides difficile-Colonized Patients
por: Fishbein, Skye R. S., et al.
Publicado: (2021)

Microbiota-Based Live Biotherapeutic RBX2660 for the Reduction of Recurrent Clostridioides difficile Infection in Older Adults With Underlying Comorbidities
por: Tillotson, Glenn, et al.
Publicado: (2022)

1796 Recovery of Clostridium difficile, Vancomycin Resistant Enterococcus and Methicillin Resistant Staphylococcus aureus from the Food of Hospitalized Patients
por: Kwon, Jennie H., et al.
Publicado: (2014)

2570. A Randomized Controlled Trial of Lactobacillus rhamnosus GG on Multidrug-Resistant Organism (MDRO) Colonization
por: Rauseo, Adriana M, et al.
Publicado: (2019)

1064. Treatment Success in Reducing Recurrent Clostridioides difficile Infection with Investigational Live Biotherapeutic RBX2660 Is Associated with Microbiota Restoration: Consistent Evidence from a Phase 3 Clinical Trial
por: Blount, Ken, et al.
Publicado: (2021)

Comparative Genomics of Antibiotic-Resistant Uropathogens Implicates Three Routes for Recurrence of Urinary Tract Infections
por: Thänert, Robert, et al.
Publicado: (2019)

691. Association between Clostridioides difficile Colonization, Rectal Swab NAAT Positivity, and Environmental Contamination
por: Lee, Mary Morgan, et al.
Publicado: (2023)

LB5. A Long-Time Coming: Final 2-year Analysis of Efficacy, Durability, and Microbiome Changes in a Controlled Open-Label Trial of Investigational Microbiota-Based Drug RBX2660 for Recurrent Clostridioides difficile Infections
por: Orenstein, Robert, et al.
Publicado: (2019)

Efficacy and Safety of RBX2660 in PUNCH CD3, a Phase III, Randomized, Double-Blind, Placebo-Controlled Trial with a Bayesian Primary Analysis for the Prevention of Recurrent Clostridioides difficile Infection
por: Khanna, Sahil, et al.
Publicado: (2022)

1042. Safety of Investigational Microbiota-Based Live Biotherapeutic RBX2660 in Individuals with Recurrent Clostridioides difficile Infection: Data from Five Prospective Clinical Studies
por: Braun, Tricia, et al.
Publicado: (2021)

167. Efficacy of Investigational Microbiota-Based Live Biotherapeutic RBX2660 in Individuals with Recurrent Clostridioides difficile Infection: Data from Five Prospective Clinical Studies
por: Bancke, Lindy, et al.
Publicado: (2021)

Publisher Correction: Efficacy and Safety of RBX2660 in PUNCH CD3, a Phase III, Randomized, Double-Blind, Placebo-Controlled Trial with a Bayesian Primary Analysis for the Prevention of Recurrent Clostridioides difficile Infection
por: Khanna, Sahil, et al.
Publicado: (2022)

Epidemiology of Plasmid Lineages Mediating the Spread of Extended-Spectrum Beta-Lactamases among Clinical Escherichia coli
por: Mahmud, Bejan, et al.
Publicado: (2022)

RBX7455, a Non-frozen, Orally Administered Investigational Live Biotherapeutic, Is Safe, Effective, and Shifts Patients’ Microbiomes in a Phase 1 Study for Recurrent Clostridioides difficile Infections
por: Khanna, Sahil, et al.
Publicado: (2020)

Interconnected microbiomes and resistomes in low-income human habitats
por: Pehrsson, Erica C., et al.
Publicado: (2016)

Functional mining of novel terpene synthases from metagenomes
por: Kwak, Suryang, et al.
Publicado: (2022)

Impact of international travel and diarrhea on gut microbiome and resistome dynamics
por: Boolchandani, Manish, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_npc4i5f7b3543n20tm6plbot5r